Exploring how KRASG12C inhibitors affect the immune response in lung cancer
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
This study is looking at a new type of treatment for non-small cell lung cancer that has a specific mutation called KRASG12C, to see how it can help not just kill cancer cells but also boost the immune system's ability to fight the cancer, and it might help doctors find better ways to use this treatment alongside other therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10899761 on NIH RePORTER |
What this research studies
This research investigates the effects of covalent inhibitors targeting the KRASG12C mutation, which is found in a significant portion of non-small cell lung cancer (NSCLC) cases. The study aims to understand how these inhibitors can not only attack cancer cells but also modify the immune environment to enhance the body's ability to fight the tumor. By examining the combination of these inhibitors with existing therapies, the research seeks to improve treatment outcomes and develop strategies to prevent resistance to therapy. Patients may benefit from insights into how their specific cancer mutations interact with immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRASG12C-mutant non-small cell lung cancer.
Not a fit: Patients without KRASG12C mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRASG12C-mutant non-small cell lung cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies and immune modulation strategies in cancer treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.